Literature DB >> 22303993

On model ensemble analyses of nonmonotonic data.

Tomas Radivoyevitch1, Charles A Kunos.   

Abstract

Mammalian ribonucleotide reductase (RNR) activity has been reported to be nonmonotonic in ATP. If many nonlinear models are to be fitted to such data automatically as part of a model search process, use of the same initial parameter values across all models can lead to too many poor fitting, monotonic least squares fits, i.e., false model rejections. We propose that such fits can be rescued by using as initial parameter estimates the final estimates of neighboring models that do have nonmonotonic fits; here models are neighbors if complexes that they represent differ by at most one ligand. We use this approach to show that troughs in RNR activity versus ATP can be fitted similarly well by models that do or do not demand a third ATP binding site.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22303993      PMCID: PMC3307047          DOI: 10.1080/15257770.2011.644370

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  13 in total

Review 1.  Structure and function of the radical enzyme ribonucleotide reductase.

Authors:  H Eklund; U Uhlin; M Färnegårdh; D T Logan; P Nordlund
Journal:  Prog Biophys Mol Biol       Date:  2001-11       Impact factor: 3.667

2.  Enzymatically active mammalian ribonucleotide reductase exists primarily as an alpha6beta2 octamer.

Authors:  Reza Rofougaran; Munender Vodnala; Anders Hofer
Journal:  J Biol Chem       Date:  2006-07-22       Impact factor: 5.157

3.  Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.

Authors:  Jun Wang; Gregory J S Lohman; JoAnne Stubbe
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-28       Impact factor: 11.205

Review 4.  Ribonucleotide reductase inhibitors and future drug design.

Authors:  J Shao; B Zhou; Bernard Chu; Y Yen
Journal:  Curr Cancer Drug Targets       Date:  2006-08       Impact factor: 3.428

Review 5.  Reduction of ribonucleotides.

Authors:  L Thelander; P Reichard
Journal:  Annu Rev Biochem       Date:  1979       Impact factor: 23.643

6.  A comprehensive model for the allosteric regulation of mammalian ribonucleotide reductase. Functional consequences of ATP- and dATP-induced oligomerization of the large subunit.

Authors:  Ossama B Kashlan; Charles P Scott; James D Lear; Barry S Cooperman
Journal:  Biochemistry       Date:  2002-01-15       Impact factor: 3.162

7.  A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage.

Authors:  H Tanaka; H Arakawa; T Yamaguchi; K Shiraishi; S Fukuda; K Matsui; Y Takei; Y Nakamura
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

8.  A ribonucleotide reductase gene is a transcriptional target of p53 and p73.

Authors:  K Nakano; E Bálint; M Ashcroft; K H Vousden
Journal:  Oncogene       Date:  2000-08-31       Impact factor: 9.867

9.  A computational model of mitochondrial deoxynucleotide metabolism and DNA replication.

Authors:  Patrick C Bradshaw; David C Samuels
Journal:  Am J Physiol Cell Physiol       Date:  2005-01-05       Impact factor: 4.249

10.  Structural basis for allosteric regulation of human ribonucleotide reductase by nucleotide-induced oligomerization.

Authors:  James Wesley Fairman; Sanath Ranjan Wijerathna; Md Faiz Ahmad; Hai Xu; Ryo Nakano; Shalini Jha; Jay Prendergast; R Martin Welin; Susanne Flodin; Annette Roos; Pär Nordlund; Zongli Li; Thomas Walz; Chris Godfrey Dealwis
Journal:  Nat Struct Mol Biol       Date:  2011-02-20       Impact factor: 15.369

View more
  1 in total

1.  Phase I Trial of Triapine-Cisplatin-Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers.

Authors:  Charles A Kunos; Edward Chu; Della Makower; Andreas Kaubisch; Mario Sznol; Susan Percy Ivy
Journal:  Front Oncol       Date:  2017-04-04       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.